Please select the eligibility criteria that correspond to the clinical trial below.
Title: International Active Surveillance Study of Women Taking Oral Contraceptives (INAS OC)
Brief Summary: The study compares the short- and long-term risks of a 24-day regimen of a drospirenone-containing oral contraceptive with the risks of established oral contraceptives in a study population that is representative for the actual users of the individual preparations.


Options:
A: Inclusion Criteria:

* First-ever OC users ("starters")
* Women switching OC use without a pill intake break ("switchers")
* Recurrent users with a pill intake break ("recurrent users")
* Women willing to participate in the active surveillance

Exclusion Criteria:

* Women who do not agree to participate
* Long-term users
B: Inclusion Criteria:

* Aged 18-35
* Body Mass Index (BMI) 19-24.9 or 30-39.9 kg/m\^2
* Willing to take birth control pills for 3-4 months
* Recent spontaneous pregnancy or cyclic menses

Exclusion Criteria:

* Contraindications to hormonal contraceptives
* Oophorectomy/Polycystic ovary syndrome (PCOS)
* Taken oral contraceptives to regulate menses recently
* Weight reduction surgery
* Used Depo-Provera within the last 12 months
* Pregnant or currently breastfeeding
* Desiring pregnancy within the next 4 months
* Unable to make study visit commitment
* Previous participation in this study
C: Inclusion Criteria:

* Age 18-35
* BMI \> 30kg/m2
* Proof of a normal breast and pelvic exam within last 9 months
* Self reported normal menstrual periods (24-35 days)
* Good general health
* In the investigator's opinion, are subject's veins suitable the repeat blood draws dictated by study protocol
* Single progesterone level during screening visit ≥ 3ng/mL
* Hematocrit ≥ 36%

Exclusion Criteria:

* Contradictions to COCs (history of deep vein thrombosis,myocardial infection, uncontrolled hypertension, pulmonary embolus, diabetes with vascular changes, stroke, migraines with neurologic changes, breast cancer, impaired liver function, uncontrolled thyroid disease, hypersensitivity or allergy to birth control)
* Smoker (must smoke 0 cigarettes)
* Actively seeking/involved in a weight loss program
* Currently pregnant/seeking pregnancy in the next 6 months
* Currently breast-feeding
* Past or current diagnosis of polycystic ovarian disease
* Recent use of birth control (Depot medroxyprogesterone: 6 months, Progestin implants: 6 months, Oral contraceptives, patch or ring: 2 months, Hormone impregnated IUD: 6 months)
* Currently taking medication that interferes with COC's (Rifampin, Carbamazepine, St. John's Wort)
D: Inclusion Criteria:

* premenopausal with a uterus and at least one ovary
* willing and able to sign the informed consent
* willing to comply with the study protocol and visit schedule
* have a body mass index of less than 25, or greater than or equal to 30
* weight stable

Exclusion Criteria:

* known or suspected pregnancy
* delivery (vaginal or cesarean) within 4 months of device insertion
* abortion (first or second trimester) within 4 months of device insertion
* contraindications to Implanon use
* hemophilia
* undiagnosed abnormal genital bleeding
* hypersensitivity or allergy to any components of Implanon
* personal or family history of thrombosis or thromboembolic disorders
* hepatic tumors or active liver disease
* known or suspected carcinoma of the breast or history of breast cancer
* more that one cardiovascular risk factor such as hypertension or diabetes
* known history of PCOS, diabetes, or glucose abnormality
* present use or use within 2 months of device insertion of a CYP3A4 inducer
* breastfeeding women
* use of an investigational drug within 2 months of device insertion
* use of injectable contraception within 6 months of device insertion
* planning a pregnancy in the next 12 months
* known HIV infection
* smoking over the age of 35

Answer: A